A Triangle pharmaceutical startup has raked in $17.5 million to fund commercialization of a nasal-spray that the company thinks could serve as an alternative to the EpiPen.
A Triangle pharmaceutical startup has raked in $17.5 million to fund commercialization of a nasal-spray that the company thinks could serve as an alternative to the EpiPen.
About Our Site:
The primary purpose of the site is to provide Real Estate & Mortgage information as it relates to today’s business environment. It can also be used to answer related question you might have about buying, selling, or financing real estate.